Extremely optimistic about the science field the Mr. Albert Bourla, President and CEO of Pfizerwho, in the context of 10th Delphi Economic Forum held in Delphi April 9-12, promised that “Soon we will see much more and much better treatments for everything”.

Specifically, Mr Bourla spoke of a rebirth, thanks to digital technology, which gives impressive synergies. “We will see much more and much better treatments for everything. This is something that science promises »he pointed out characteristics. At this point, he welcomed the contribution of artificial intelligence, which will undertake many processes, but without replacing the researchers.

“Researchers will use AI and instead of bringing cancer treatment in 10 years, they will bring it to 4 years.” He explained, among other things, that we are not planning to reduce our people or our budget, which amounts to $ 11 billion.

The greatest benefit, he added, is to increase productivity, as with the same money we will offer more medicines and more treatments. Concerning the goals of the coming years, Pfizer’s CEO mainly referred to the elimination of Alzheimer’s and the treatment of many forms of cancer, which will be converted into chronic diseases in the future, such as diabetes mellitus.

At the same time, on the occasion of Pfizer’s investment in Thessaloniki, Mr Bourla argued that Greece is innovative and what it needs to acquire is the opportunity to innovate. Indeed, it praised the contribution of the current government, describing its views as the most progressive in the field of European industry. And he made it clear that Pfizer did not encounter obstacles in Greece, as despite the concerns “everything went very well”. So, instead of the 200 people we initially designed, we currently employ 1,200 people in Thessaloniki, he continued, not excluding Pfizer’s further investment in the country.

Elsewhere in the debate, Mr Bourla referred to the US, explaining that in the US we have a government that is implementing radical policies that will affect the world. “I am in touch with the president and the government and we are discussing all the issues,” he said, welcoming the fact that the pharmaceutical industry has been excluded from the duties. “I do not know if the exception will be maintained, as the most important feature of the crisis is uncertainty. But it is better to have been excluded than to have been included »commented.

However, he did not fail to refer to the risk of turmoil in the supply chains, as offering raw materials cannot be replaced by internal production. “There is no time, but it would have been much more expensive than China”. In the field of medicines, of course, he clarified that the cost of raw materials is very low, as most resources are in research and development. In any case, he pointed out that Europe and the US can find solutions, though everything is uncertain.

So, completed, ‘We have to be ready for any possibility […] We need to have ready plans to reduce the impact ». Finally, she made a reference to Europe’s competitiveness, describing bureaucracy as a basic trade, as well as her reluctance to pay for innovation. “The research was mainly done in Europe 20 years ago. But everyone has left and everyone has gone to the US. “he ended up.